Article Sidebar

Submitted
11 April 2021
Accepted
30 November 2022
Published
14 April 2021
Download
PDF
Statistic
Read Counter : 623 Download : 471

Main Article Content

Abstract

Thyroid cancer  is one of the commonest cancer  while the incidence of occult thyroid cancer is only 0,05%. Completion total thyroidectomy as one of the treatment choice for thyroid cancer which initially diagnosed preoperatively as benign thyroid mass, remains controversial. The aim of this study is to understand the effectiveness of completion total thyroidectomy after partial thyroidectomy, by analyzing from: proportion of malignant contralateral thyroid tissue, post operative complications, and recurrence of cancer. This retrospective study collected medical record datan between 2011 and 2016. Total sample were 16 patients (15 females, 1 male). There was no significant difference on contralateral thyroid  tissue malignancy proportion between completion total thyroidectomy and without total thyroidectomy (p=0,375). It was found 3 surgical complications (50%) from 6 patients with completion total thyroidectomy and 3 complications (30%) from 10 patients without completion total thyroidectomy. The complications were temporary injury of recurrent laryngeal nerve (p=0,511), seroma (p=0,375), and hypoparathyroidism (p=0,375). No recurrence event after 4 years follow up amount both groups. In conclusion, there is no advantage in completion total thyroidectomy analized from proportion of malignant contralateral thyroid tissue, post operative complication and recurrence in 4 years-follow up.

Keywords

occult thyroid cancer partial thyroidectomy completion total thyroidectomy

Article Details

License

Copyright (c) 2021 Folia Medica Indonesiana

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Syahrudi, S., & Wijayahadi, R. Y. (2021). Completion Total Thyroidectomy in Occult Thyroid Cancer Patients after Partial Thyroidectomy. Folia Medica Indonesiana, 57(1), 11–15. https://doi.org/10.20473/fmi.v57i1.26328
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. American Diabetes Association (2017). Standards of medical care in diabetes. Diabetes Care: The Journal of Clinical and Applied Research and Education 40, supplement 1
  2. American Society of Health System Pharmacist (2011). AHFS Drug Information. Unites States of America
  3. Bellia A, Rizza S, Galli A, Fabiano R, Donadel G, Lombardo MF, Cardillo C, Sbraccia P, Tesauro M, Lauro D (2010). Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes . Atherosclerosis 210, 199-201
  4. Chehade JM, Gladysz M, Mooradian AD (2013). Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs 73, 327-339
  5. Davignon J (2004). Beneficial cardiovascular pleiotropic effects of statins. Circulation 109, III39–43
  6. Deerochanawong C, Buranakitjaroen P, Nitiyanant W, Suwantamee J, Piamsomboon C, Vongthavaravat V, Suwanwela C, Kosachunhanun N, Sukonthasarn A (2007). The atorvastatin goal achievement across risk
  7. levels: (ATGOAL) study in Thailand . J Med Assoc Thai 90, 72-81
  8. Grossman A, Grossman E (2017). Blood pressure control in type 2 diabetic patients. Cardiovascular Diabetology 16, 1-15
  9. Lexicomp (2016). Drug Information Handbook. In: Lacy C, Armstrong L, Goldman M, Lance L (eds). Ohio, Lexi-Comp Inc, p 174-177
  10. Ministry of Health (2013). Badan Penelitian dan Pengembangan Kesehatan Kementrian Kesehatan Republik Indonesia. Jakarta
  11. Paneni F, Beckman JA, Creager MA, Cosentino F (2013). Diabetes and vascular disease: pathophysiology, clinical consequences, and medical
  12. therapy: part I. Eur Heart J 34, 2436-2446
  13. PERKENI (2015). Konsensus pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia. Jakarta, PB PERKENI, p 1-79
  14. Schachter M (2005). Chemical, pharmacokinetic and pharmacodinamic properties of statin : an update. Fundam Clin Pharmacol 19, 117-125
  15. Shaw JE, Sicree RA, Zimmet PZ (2010). Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87, 4-14
  16. Stancu C, Sima A (2001). Statins: mechanism of action and effects. J Cell Mol Med 5, 378-387
  17. Triplitt C, Reasner C (2011). Diabetes mellitus. In: DiPiro J, Talbert RL, Yee G, Matzkee G, Wells B, Posey LM. Pharmacotherapy: a pathophysiologic approach 8th ed, New York, McGraw-Hill
  18. Tousoulis D, Oikonomou E, Economou EK, Crea F, Kaski JC (2016). Inflammatory cytokines in atherosclerosis: current therapeutic approaches. Eur Heart J 37, 1723-1732
  19. Wu L, Parhofer KG (2014). Diabetic dyslipidemia. Metabolism 63, 1469-1479
  20. Zhou Q, Liao JK (2010). Pleiotropic effects of statins: basic research and clinical perspectives. Circ J 74, 818-826